104 related articles for article (PubMed ID: 38966681)
1. Chronic Kidney Disease Stage and Cardiovascular and Mortality Events Among Older Adults: The SPRINT Trial.
Turbay-Caballero V; Ricardo AC; Chen J; Missikpode C; Lash JP; Aroca-Martinez G; Musso CG
Kidney Med; 2024 Jul; 6(7):100845. PubMed ID: 38966681
[TBL] [Abstract][Full Text] [Related]
2. Kidney Function as Risk Factor and Predictor of Cardiovascular Outcomes and Mortality Among Older Adults.
Kühn A; van der Giet M; Kuhlmann MK; Martus P; Mielke N; Ebert N; Schaeffner ES
Am J Kidney Dis; 2021 Mar; 77(3):386-396.e1. PubMed ID: 33197533
[TBL] [Abstract][Full Text] [Related]
3. Prevention of heart failure events with intensive versus standard blood pressure lowering across the spectrum of kidney function and albuminuria: a SPRINT substudy.
Vaduganathan M; Pareek M; Kristensen AMD; Biering-Sørensen T; Byrne C; Almarzooq Z; Olesen TB; Olsen MH; Bhatt DL
Eur J Heart Fail; 2021 Mar; 23(3):384-392. PubMed ID: 33448580
[TBL] [Abstract][Full Text] [Related]
4. Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.
Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Blais J; Li Q; Jardine MJ; Perkovic V; Wheeler DC
Am J Kidney Dis; 2021 Jan; 77(1):23-34.e1. PubMed ID: 32971190
[TBL] [Abstract][Full Text] [Related]
5. Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
Waijer SW; Vart P; Cherney DZI; Chertow GM; Jongs N; Langkilde AM; Mann JFE; Mosenzon O; McMurray JJV; Rossing P; Correa-Rotter R; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL
Diabetologia; 2022 Jul; 65(7):1085-1097. PubMed ID: 35445820
[TBL] [Abstract][Full Text] [Related]
6. Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis.
; Grams ME; Coresh J; Matsushita K; Ballew SH; Sang Y; Surapaneni A; Alencar de Pinho N; Anderson A; Appel LJ; Ärnlöv J; Azizi F; Bansal N; Bell S; Bilo HJG; Brunskill NJ; Carrero JJ; Chadban S; Chalmers J; Chen J; Ciemins E; Cirillo M; Ebert N; Evans M; Ferreiro A; Fu EL; Fukagawa M; Green JA; Gutierrez OM; Herrington WG; Hwang SJ; Inker LA; Iseki K; Jafar T; Jassal SK; Jha V; Kadota A; Katz R; Köttgen A; Konta T; Kronenberg F; Lee BJ; Lees J; Levin A; Looker HC; Major R; Melzer Cohen C; Mieno M; Miyazaki M; Moranne O; Muraki I; Naimark D; Nitsch D; Oh W; Pena M; Purnell TS; Sabanayagam C; Satoh M; Sawhney S; Schaeffner E; Schöttker B; Shen JI; Shlipak MG; Sinha S; Stengel B; Sumida K; Tonelli M; Valdivielso JM; van Zuilen AD; Visseren FLJ; Wang AY; Wen CP; Wheeler DC; Yatsuya H; Yamagata K; Yang JW; Young A; Zhang H; Zhang L; Levey AS; Gansevoort RT
JAMA; 2023 Oct; 330(13):1266-1277. PubMed ID: 37787795
[TBL] [Abstract][Full Text] [Related]
7. Progression of Chronic Kidney Disease Risk Categories and Risk of Cardiovascular Disease and Total Mortality: Coronary Artery Risk Development in Young Adults Cohort.
Choi Y; Jacobs DR; Shroff GR; Kramer H; Chang AR; Duprez DA
J Am Heart Assoc; 2022 Nov; 11(21):e026685. PubMed ID: 36314497
[TBL] [Abstract][Full Text] [Related]
8. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
[TBL] [Abstract][Full Text] [Related]
9. Kidney function measures and cardiovascular outcomes in people with diabetes: the Hoorn Diabetes Care System cohort.
Dal Canto E; Elders PJM; van der Heijden AA; van Ballegooijen AJ; Lissenberg-Witte BI; Rutters F; Beulens JWJ
Diabetologia; 2023 Mar; 66(3):482-494. PubMed ID: 36347992
[TBL] [Abstract][Full Text] [Related]
10. Changes in GFR and Albuminuria in Routine Clinical Practice and the Risk of Kidney Disease Progression.
Neuen BL; Weldegiorgis M; Herrington WG; Ohkuma T; Smith M; Woodward M
Am J Kidney Dis; 2021 Sep; 78(3):350-360.e1. PubMed ID: 33895181
[TBL] [Abstract][Full Text] [Related]
11. Cognitive Function and Kidney Disease: Baseline Data From the Systolic Blood Pressure Intervention Trial (SPRINT).
Weiner DE; Gaussoin SA; Nord J; Auchus AP; Chelune GJ; Chonchol M; Coker L; Haley WE; Killeen AA; Kimmel PL; Lerner AJ; Oparil S; Saklayen MG; Slinin YM; Wright CB; Williamson JD; Kurella Tamura M;
Am J Kidney Dis; 2017 Sep; 70(3):357-367. PubMed ID: 28606731
[TBL] [Abstract][Full Text] [Related]
12. Association of estimated glomerular filtration rate and urine albumin-to-creatinine ratio with incidence of cardiovascular diseases and mortality in chinese patients with type 2 diabetes mellitus - a population-based retrospective cohort study.
Fung CS; Wan EY; Chan AK; Lam CL
BMC Nephrol; 2017 Feb; 18(1):47. PubMed ID: 28152985
[TBL] [Abstract][Full Text] [Related]
13. Nonalbuminuric Diabetic Kidney Disease and Risk of All-Cause Mortality and Cardiovascular and Kidney Outcomes in Type 2 Diabetes: Findings From the Hong Kong Diabetes Biobank.
Jin Q; Luk AO; Lau ESH; Tam CHT; Ozaki R; Lim CKP; Wu H; Jiang G; Chow EYK; Ng JK; Kong APS; Fan B; Lee KF; Siu SC; Hui G; Tsang CC; Lau KP; Leung JY; Tsang MW; Kam G; Lau IT; Li JK; Yeung VT; Lau E; Lo S; Fung S; Cheng YL; Chow CC; Huang Y; Lan HY; Szeto CC; So WY; Chan JCN; Ma RCW;
Am J Kidney Dis; 2022 Aug; 80(2):196-206.e1. PubMed ID: 34999159
[TBL] [Abstract][Full Text] [Related]
14. Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diabetes.
Nichols GA; Déruaz-Luyet A; Brodovicz KG; Kimes TM; Rosales AG; Hauske SJ
BMC Nephrol; 2020 May; 21(1):167. PubMed ID: 32380961
[TBL] [Abstract][Full Text] [Related]
15. Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes.
Filippatos G; Anker SD; Pitt B; Rossing P; Joseph A; Kolkhof P; Lambelet M; Lawatscheck R; Bakris GL; Ruilope LM; Agarwal R
JACC Heart Fail; 2022 Nov; 10(11):860-870. PubMed ID: 36328655
[TBL] [Abstract][Full Text] [Related]
16. Diabetic kidney disease and risk of incident stroke among adults with type 2 diabetes.
Kaze AD; Jaar BG; Fonarow GC; Echouffo-Tcheugui JB
BMC Med; 2022 Mar; 20(1):127. PubMed ID: 35346165
[TBL] [Abstract][Full Text] [Related]
17. Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone.
Agarwal R; Pitt B; Rossing P; Anker SD; Filippatos G; Ruilope LM; Kovesdy CP; Tuttle K; Vaduganathan M; Wanner C; Bansilal S; Gebel M; Joseph A; Lawatscheck R; Bakris GL
JAMA Cardiol; 2023 Aug; 8(8):732-741. PubMed ID: 37314801
[TBL] [Abstract][Full Text] [Related]
18. CVD risk in non-albuminuric chronic kidney disease in hypertensive, non-diabetic subjects: A
Sheng CS; Wang D; Yuan J; Cheng Y; Sun S; Yang Y; Miao Y; Wang W; Tian J; Bloomgarden ZT
Front Cardiovasc Med; 2022; 9():977938. PubMed ID: 36568559
[TBL] [Abstract][Full Text] [Related]
19. Estimated GFR Variability and Risk of Cardiovascular Events and Mortality in SPRINT (Systolic Blood Pressure Intervention Trial).
Malhotra R; Katz R; Jotwani V; Agarwal A; Cohen DL; Cushman WC; Ishani A; Killeen AA; Kitzman DW; Oparil S; Papademetriou V; Parikh CR; Raphael KL; Rocco MV; Tamariz LJ; Whelton PK; Wright JT; Shlipak MG; Ix JH
Am J Kidney Dis; 2021 Jul; 78(1):48-56. PubMed ID: 33333147
[TBL] [Abstract][Full Text] [Related]
20. Estimated Kidney Tubular Secretion and Kidney, Cardiovascular, and Mortality Outcomes in CKD: The Systolic Blood Pressure Intervention Trial.
Ascher SB; Shlipak MG; Katz R; Bullen AL; Scherzer R; Hallan SI; Cheung AK; Raphael KL; Estrella MM; Jotwani VK; Seegmiller JC; Ix JH; Garimella PS
Kidney Med; 2022 Dec; 4(12):100546. PubMed ID: 36507053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
